Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics 2024, 13, 874
Patient | Age, yr (Sex) | Underlying Disease | CCI | Type of Infection | Bacterial Species | Bacteremia | Drainable Source/Drainage Performed | Additional Therapy | Days of Treatment | Clinical Failure at Day 14 | Mortality at Day 30 |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 82 (M) | Renal transplant recipient | 7 | Primary bacteremia | P. aeruginosa | Yes | No | No | 8 | Yes | Yes |
2 | 89 (M) | Chronic ischemia right lower limb | 14 | Chronic osteomyelitis | E. cloacae | No | Yes/Yes: Limb amputation | No | 13 | No | Yes |
3 | 63 (M) | Lung transplant recipient | 2 | Previous ECMO cannula wound infection | Raoultella ornithinolytica, E. coli | No | Yes/Yes: Resection of the infected wound | No | 13 | No | No |
4 | 76 (F) | Diverticulitis | 4 | Postoperative deep wound infection | Achromobacter sp., P. aeruginosa | No | Yes/No: Undrained abscess | No | 8 | No | No |
5 | 56 (M) | COVID-19 pneumonia | 3 | Primary bacteremia and ECMO cannula infection | Achromobacter sp. | Yes | Yes/No: ECMO cannula not retired | Intravenous colistin (after 22 days of cefiderocol) | 27 | Yes | Yes |
6 | 39 (M) | COVID-19 pneumonia in a lung transplant recipient | 1 | ECMO cannula wound infection + tracheobronchitis | P. aeruginosa | No | Yes/No: ECMO cannula not retired | Nebulized colistin | 6 | Yes | Yes |
7 | 51 (M) | Acute pancreatitis | 2 | Catheter-associated urinary infection | Achromobacter sp. | No | No | No | 11 | No | Yes |
8 | 78 (F) | Renal transplant recipient | 10 | Femoro-femoral bypass graft infection | E. cloacae | No | Yes/No: By-pass not explanted | No | 13 | No | No |
9 | 65 (M) | Renal transplant recipient | 6 | Obstructive pyelonephritis | E. cloacae, P. aeruginosa | Yes | Yes/Yes: Ureteral stent placement | No | 27 | No | No |
10 | 59 (M) | Acute myeloid leukemia and recent allo-HSCT | 3 | Tonsillar abscess | P. aeruginosa | Yes | Yes/No: Undrained abscess | Intravenous amikacin (during the first 3 days) | 22 | Yes | Yes |
11 | 41 (M) | NK/T-cell lymphoma | 2 | Infected pancreatic necrosis | P. aeruginosa | No | Yes/Yes: Abscess drainage | No | 62 | No | No |
12 | 56 (F) | Follicular lymphoma with persistent COVID-19 | 2 | Catheter-associated UTI | Achromobacter sp. | No | No | No | 5 | No | No |
13 | 67 (M) | Lung transplant recipient | 2 | Acute tracheobronchitis | P. aeruginosa | No | No | Nebulized colistin | 7 | No | No |
14 | 77 (F) | Acute myeloid leukemia | 5 | Soft tissue infection | P. aeruginosa | No | No | No | 14 | No | No |
15 | 61 (M) | Hemorrhagic shock | 7 | Catheter-associated UTI | Achromobacter sp. | No | No | No | 7 | No | Yes |
16 | 56 (M) | Tibial osteomyelitis | 0 | Chronic osteomyelitis | P. putida | No | Yes/Yes: Osteomyelitis debridement | No | 14 | No | No |
17 | 70 (M) | COPD | 5 | Nosocomial pneumonia | P. aeruginosa | Yes | No | No | 25 | No | Yes |
18 | 51 (M) | Renal transplant recipient | 3 | Renal graft pyelonephritis | P. aeruginosa | No | No | No | 17 | No | No |
19 | 54 (M) | Elbow osteomyelitis | 1 | Osteosynthesis-associated infection | E. cloacae | No | Yes/Yes: Osteosynthesis implant removal | No | 32 | No | No |
20 | 58 (M) | Renal transplant recipient | 4 | Postoperative deep wound infection | P. aeruginosa | No | Yes/No: Undrained abscess | No | 28 | No | No |
21 | 67 (M) | Lung transplant recipient | 4 | Acute tracheobronchitis | P. aeruginosa | Yes | No | Nebulized colistin | 15 | No | No |
22 | 54 (F) | Lung transplant recipient | 3 | Acute tracheobronchitis | Enterobacter hormaechei | No | No | Nebulized amikacin | 6 | No | No |
23 | 45 (M) | Richter’s Syndrome | 2 | Intestinal bacterial translocation | P. aeruginosa | Yes | No | No | 9 | Yes | Yes |
24 | 53 (F) | Open tibia fracture | 1 | Tibial osteomyelitis | P. aeruginosa | No | Yes/Yes: Osteomyelitis debridement | No | 38 | No | No |
25 | 54 (F) | Metastatic kidney cancer | 5 | Catheter-related bloodstream infection | P. aeruginosa | Yes | Yes/Yes: Catheter removal | No | 5 | No | No |
26 | 78 (F) | Renal transplant recipient | 9 | Postoperative deep wound infection | P. putida | No | Yes/Yes: Abscess drainage | No | 41 | No | No |
27 | 44 (F) | Renal transplant recipient | 3 | Postoperative deep wound infection | P. putida | No | Yes/No: Undrained abscess | No | 12 | No | No |
28 | 49 (M) | Lung transplant recipient | 4 | Acute tracheobronchitis | P. aeruginosa | No | No | No | 14 | No | No |
29 | 75 (M) | Status epilepticus | 3 | Ventilator-associated pneumonia | P. aeruginosa | No | No | Nebulized colistin | 9 | No | No |
30 | 77 (M) | Multiple organ dysfunction syndrome | 8 | Acute tracheobronchitis | P. aeruginosa | No | No | No | 10 | No | No |
31 | 59 (F) | Pulmonary fibrosis | 1 | Acute tracheobronchitis | P. aeruginosa | No | No | Nebulized colistin | 8 | No | No |
32 | 80 (M) | Meige syndrome (tracheostomy) | 4 | Acute tracheobronchitis | P. aeruginosa | No | No | Nebulized aztreonam | 10 | No | No |
33 | 56 (M) | Acute lymphoblastic leukemia | 4 | Prostatic abscess | P. aeruginosa | No | Yes/No: Undrained abscess | No | 33 | No | No |
34 | 63 (M) | Renal transplant recipient | 5 | Renal graft pyelonephritis | P. putida | No | No | No | 18 | No | No |
Reference
- Kirkegaard-Biosca, C.; del Barrio-Tofiño, E.; Villamarín, M.; Larrosa, N.; Campany, D.; González-López, J.J.; Ferrer, R.; Viñado, B.; Doménech, L.; Sellarès-Nadal, J.; et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics 2024, 13, 874. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kirkegaard-Biosca, C.; del Barrio-Tofiño, E.; Villamarín, M.; Larrosa, N.; Campany, D.; González-López, J.J.; Ferrer, R.; Viñado, B.; Doménech, L.; Sellarès-Nadal, J.; et al. Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics 2024, 13, 874. Antibiotics 2025, 14, 4. https://doi.org/10.3390/antibiotics14010004
Kirkegaard-Biosca C, del Barrio-Tofiño E, Villamarín M, Larrosa N, Campany D, González-López JJ, Ferrer R, Viñado B, Doménech L, Sellarès-Nadal J, et al. Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics 2024, 13, 874. Antibiotics. 2025; 14(1):4. https://doi.org/10.3390/antibiotics14010004
Chicago/Turabian StyleKirkegaard-Biosca, Cristina, Ester del Barrio-Tofiño, Miguel Villamarín, Nieves Larrosa, David Campany, Juan José González-López, Ricard Ferrer, Belén Viñado, Laura Doménech, Julia Sellarès-Nadal, and et al. 2025. "Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics 2024, 13, 874" Antibiotics 14, no. 1: 4. https://doi.org/10.3390/antibiotics14010004
APA StyleKirkegaard-Biosca, C., del Barrio-Tofiño, E., Villamarín, M., Larrosa, N., Campany, D., González-López, J. J., Ferrer, R., Viñado, B., Doménech, L., Sellarès-Nadal, J., Escolà-Vergé, L., Fernández-Hidalgo, N., & Los-Arcos, I. (2025). Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics 2024, 13, 874. Antibiotics, 14(1), 4. https://doi.org/10.3390/antibiotics14010004